Inozyme Pharma Stock Net Asset
| INZYDelisted Stock | USD 4.00 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Inozyme Pharma's long-term financial health and intrinsic value.
Inozyme |
Inozyme Pharma Company Net Asset Analysis
Inozyme Pharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Inozyme Pharma Net Asset | 123.18 M |
Most of Inozyme Pharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inozyme Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Inozyme Pharma has a Net Asset of 123.18 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Inozyme Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.Inozyme Pharma is currently under evaluation in net asset category among its peers.
Inozyme Fundamentals
| Return On Equity | -1.42 | |||
| Return On Asset | -0.48 | |||
| Current Valuation | 220.43 M | |||
| Shares Outstanding | 64.56 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 94.29 % | |||
| Number Of Shares Shorted | 3.38 M | |||
| Price To Book | 8.12 X | |||
| EBITDA | (104.03 M) | |||
| Net Income | (102.02 M) | |||
| Cash And Equivalents | 151.48 M | |||
| Cash Per Share | 3.77 X | |||
| Total Debt | 46.87 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 14.54 X | |||
| Book Value Per Share | 0.49 X | |||
| Cash Flow From Operations | (91.91 M) | |||
| Short Ratio | 0.78 X | |||
| Earnings Per Share | (1.68) X | |||
| Price To Earnings To Growth | (0.06) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 67 | |||
| Beta | 2.29 | |||
| Market Capitalization | 258.25 M | |||
| Total Asset | 123.18 M | |||
| Retained Earnings | (387.95 M) | |||
| Working Capital | 86.78 M | |||
| Net Asset | 123.18 M |
About Inozyme Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Inozyme Stock
If you are still planning to invest in Inozyme Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Inozyme Pharma's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |